BofA raised the firm’s price target on BWX Technologies to $115 from $82 and keeps a Buy rating on the shares. BWX is “uniquely positioned to two major emerging secular themes,” namely the submarine buildup in defense and the increasing role of nuclear power for green and secure energy, the analyst tells investors. In addition, EBITDA profitability and expansion into therapeutics makes BWXT Medical a “fundamentally more attractive business,” the analyst contends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWXT: